Antibodies against human interleukin-13 and pharmaceutical compositions thereof

US7615213B2 · kind B2 · utility

Assignee

• Wyeth, LLC · US

Inventors

• Marion T. Kasaian · Boston, US
• Lioudmila Tchistiakova · Andover, US
• Geertruida M. Veldman · Sudbury, US
• Kimberly Ann Marquette · Somerville, US
• Xiang-Yang Tan · Reading, US
• Debra Donaldson · Cambridge, US
• Laura Lin · Weston, US
• Tania Shane · Newton, US
• Amy Sze Pui Tam · Medford, US
• Eric Feyfant · Lexington, US
• Nancy L. Wood · Cambridge, US
• Lori Fitz · Arlington, US
• Angela Widom · Acton, US
• Kevin D. Parris · Newton, US
• Samuel Goldman · Acton, US
• Jose Saldanha · Ormskirk, GB

Key dates

• Filing date: Jun 9, 2005
• Grant date: Nov 10, 2009
• Expiry date: Jul 18, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.